Clinical Endocrinology Update

STATEMENT OF INDEPENDENCE

The scientific content of the Clinical Endocrinology Update (CEU) 2016 Session Recordings was developed by the CEU Steering Committee, independent of and prior to the solicitation of grant support. As a provider of independent and continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous.
While the CEU 2016 Session Recordings do not offer AMA PRA Category 1 Credits™, its content was developed, in accordance with the ACCME's Essential Areas and Elements, including the Standards for Commercial Support. The commercial supporters of this meeting have no influence over topics or speakers. Educational grants support the production costs of the overall activity and are not used to compensate speakers in supported sessions.

LEARNING OBJECTIVES

Upon completion of this educational activity, learners will be able to:
  • Discuss state-of-the-art research in endocrinology
  • Demonstrate updated knowledge of the diagnosis and treatment of diabetes, lipid, osteoporosis, pituitary, adrenal, thyroid, and reproductive endocrine disorders
  • Employ enhanced skills and practice management techniques to improve patient care

TARGET AUDIENCE

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, primary care and internal medicine physicians, and healthcare professionals who treat and care for patients with endocrine disorders, as well as others seeking an update in recent developments in the treatment of endocrine disorders.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard J. Auchus, MD, PhD: Consultant/Scientific Advisory Board Member, Alder BioPharmaceuticals, Corcept Therapeutics, Diurnal LTD, Innocrin Pharmaceuticals, Janssen Pharmaceuticals, Laboratory Corporation of America, Novartis Pharmaceuticals, Spruce Biosciences, Tokai Pharmaceuticals; Research Funding, Millendo Therapeutics, Neurocrine Biosciences, Novartis Pharmaceuticals, Strongbridge Biopharma
Elizabeth L. Barrett-Connor, MD: Advisory Board Member, Eli Lilly & Co.
Rhonda M. Bentley-Lewis, MD, MMSc: Consultant, Sanofi-Aventis, Merck Sharp and Dohme, Inc., Novartis Pharmaceuticals; Author, Up-to-Date; Consultant (Spouse), Danaher-Lagnese Law Firm, Health Research Associates, Novartis Pharmaceuticals, Sanofi-Aventis
Sarah L. Berga, MD: Site Primary Investigator, Ferring Pharmaceuticals Inc.
Daniel H. Bessesen, MD: Data Safety Monitoring Board Member, Enteromedics Inc.
James W. Findling, MD: Research Funding, Corcept Therapeutics, Millendo Therapeutics, Novartis Pharmaceuticals
Anne C. Goldberg, MD: Consultant and Research Funding, Regeneron, Sanofi-Aventis; Consultant, OptumRx, uniQuire; Editor, Merck & Co., Inc. Manual of Diagnosis and Therapy; Research Funding, Amarin Pharma, Inc., Amgen, Genentech/Roche, Genzyme, Glaxo-Smith-Kline, Ionis Pharmaceuticals, Merck & Co., Inc., Pfizer Inc.
Jennifer B. Green, MD: Consultant, Boehringer Ingelheim Pharmaceuticals, Inc. & Lilly USA, LLC, Daiichi; Consultant, Research Funding, and Speaker, Merck & Co., Inc.; Research Funding, AstraZeneca, Glaxo-Smith-Kline
Irl B. Hirsch, MD: Consultant, Abbott Diabetes Care, Intarcia, Roche
Keith A. Hruska, MD: Consultant, Vifor; Consultant and Grant Support, Celgene
Suzanne M. Jan de Beur, MD: Consultant and Research Funding, Ultragenyx
Laurence Katznelson, MD: Consultant, Chiasma; Consultant and Research Funding, Novartis Pharmaceuticals, Versartis
Janet B. McGill, MD: Consultant, Boehringer Ingelheim Pharmaceuticals, Inc. & Lilly USA, LLC, Calibra Medical, Merck & Co. Inc.; Consultant and Speaker, Janssen Pharmaceuticals; Consultant and Research Funding, Novo Nordisk Inc.; Research Funding, Dexcom, Inc., Lexicon Pharmaceuticals, Inc., Novartis Pharmaceuticals
Anne L. Peters, MD: Advisory Board Member/Consultant, Abbott Diabetes Care, Becton Dickinson, Bigfoot Biomedical, Biodel, Boehringer Ingelheim Pharmaceuticals, Inc. & Lilly USA, LLC, CVS/Caremark, Astra-Zeneca, Intarcia, Janssen Pharmaceuticals, Lexicon, Medtronic-Minimed, Merck & Co. Inc., Novo Nordisk Inc., Omada Health, OptumRx, Thermalin; Research Funding, Janssen Pharmaceuticals, Medtronic Foundation; Editorial Fees, Medscape
Roberto R. Salvatori, MD: Consultant, Pfizer Inc., Novo Nordisk Inc.
Garry S. Tobin, MD: Speaker, Eli Lilly & Co., Janssen Pharmaceuticals, Novo Nordisk Inc.
Nicholas A. Tritos, MD, DSc: Research Funding, Ipsen Pharmaceuticals, Novartis Pharmaceuticals, Novo Nordisk Inc., Pfizer Inc.
Joseph G. Verbalis, MD: Consultant and Desmopressin Safety Board Member, Ferring Pharmaceuticals; Consultant, Otsuka Pharmaceuticals
Steven G. Waguespack, MD: Advisory Board Member, Eisai Inc.
Carol H. Wysham, MD: Consultant and Speaker, AstraZeneca, Boerhinger Ingelheim, Eli Lilly & Co., Janssen Pharmaceuticals, Novo Nordisk Inc., Sanofi-Aventis
William F. Young, Jr., MD, MSc: Consultant, Glaxo-Smith-Kline, Nihon Medi-Physics Co., Ltd.
The following faculty reported no relevant financial relationships: Bradley D. Anawalt, MD; Thomas A. Buchanan, MD; Alan Chait, MD; Maria L. Collazo-Clavell, MD; David S. Cooper, MD; Alan C. Dalkin, MD George J. Kahaly, MD, PhD; M. Carol Greenlee, MD; William H. Herman, MD, MPH; Stephanie L. Lee, MD, PhD; Susan J. Mandel, MD, MPH; Connie B. Newman, MD; Harold N. Rosen, MD; Lisa R. Tannock, MD; Joshua D. Safer, MD; Robert A. Wermers, MD

The CEU Steering Committee members who planned and/or reviewed content for this activity reported the following relevant financial relationship(s):

George A. Bray, MD: Advisory Board Member, Herbalife Nutrition Institute, Medifast, Inc.; Speakers Bureau, Novo Nordisk Inc.
Kathleen M. Dungan, MD, MPH: Author, Up-to-Date; Consultant, Eli Lilly & Co.; Consultant and Research Funding, Glaxo-Smith-Kline; Editor and Author, ENDO Text; Program Director and Author, eDiabetes Review; Speaker, Janssen Pharmaceuticals; Speaker and Research Funding, AstraZeneca; Research Funding, Merck & Co., Inc., Novo Nordisk Inc., Regeneron, Sanofi-Aventis
Maria Fleseriu, MD: Board of Directors Member, Pituitary Society; Research Funding, Novo Nordisk Inc.; Scientific Consultant and Research Funding, Chiasma, Novartis Pharmaceuticals, Strongbridge Biopharma, Ipsen Pharmaceuticals, Pfizer Inc.
Jennifer A. Sipos, MD: Editorial Board Member, American Thyroid Association (Thyroid), National Institutes for Health Physicians Data Query (Cancer Genetics); Consultant and Speakers Bureau, Genzyme
Priyathama Vellanki, MD: Consultant and Research Funding, Merck & Co., Inc.; Editorial Board Member, Endocrine Web; Research Funding, Boehringer Ingelheim Pharmaceuticals, Inc. & Lilly USA, LLC
The following CEU Steering Committee members who planned and/or reviewed content for this activity reported no relevant financial relationships: David S. Cooper, MD; Ann E. Kearns, MD, PhD; Janet A. Schlechte, MS, MD
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

Use of professional judgment:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

Drugs and dosages:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such off-label use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

The live activity from which these session recordings are derived was supported by educational grants from AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc. & Lilly USA, LLC; Corcept Therapeutics Inc.; Dexcom, Inc.; Eisai Inc.; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corp.; Novo Nordisk Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer, Inc.; and Shire.

AMA PRA CATEGORY 1 CREDIT™ (CME) INFORMATION

This series of webcasts is not available for credit.

SYSTEM REQUIREMENTS

Your system must meet the following requirements:
Computer: with minimum processor and memory as recommended by operating system manufacturer
Operating System: Windows: 7, 8, 10. Macintosh OSX
Internet Browser: consult the detailed system requirements page to determine the browser version required by Adobe Flash on your computer’s operating system.
Players & Plugins: an up-to-date version of Adobe Flash Player
Audio: Functioning sound card with attached speakers installed
Internet Connection: a broadband Internet connection
Please review the detailed system requirements page for more information and troubleshooting steps.
LAST REVIEW DATE: September 9, 2016
For technical assistance or information, please contact support@endosessions.org.
For questions about content, please contact the Endocrine Society at education.endocrine.org/contact.